BIOQUAL announced the retirement of John C. Landon as Chief Executive Officer. Effective June 3, 2013, Dr. Mark G. Lewis was appointed to succeed Dr. Landon as CEO. BIOQUAL's Board of Directors had appointed Dr. Lewis as BIOQUAL's President on November 15, 2010, based in part on the belief that Dr. Lewis would be a strong candidate as a successor CEO.
Dr. Landon will also retire as an employee of BIOQUAL on August 14, 2013, but will continue as Chairman of the BIOQUAL Board of Directors. Dr. Lewis joined BIOQUAL as Senior Scientist in August 2003. He became the Executive Vice President in October 2008, and served in that capacity until he became President in 2010.
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
BIOQUAL, INC. 